<img src="https://ml.globenewswire.com/Resource/Download/908fb457-7f8e-4a08-9081-5565e3dfb3d7?size=2" nborder="0" align="left" hspace="5" vspace="5" title="22157.jpg" alt="Company Logo"/>Dublin, Sept. 09, 2026 <a href="https://www.globenewswire.com" target="_blank">(GLOBE NEWSWIRE)</a> -- The <a href="https://www.researchandmarkets.com/reports/6274242/dna-gene-cloning-services-market-insights?utm_source=GNE&amp;utm_medium=PressRelease&amp;utm_code=4rg43x&amp;utm_campaign=2346356+-+Global+DNA+and+Gene+Cloning+Services+Market+to+Reach+%2415.6+Billion+by+2034+as+Therapeutic+Pipelines+Expand+and+Organizations+Adopt+Outsourced%2c+Technology-Enabled+Molecular+Biology+Services&amp;utm_exec=jocamsai" rel="nofollow" target="_blank" title="DNA and Gene Cloning Services - Market Insights, Competitive Landscape, and Market Forecast - 2034">"DNA and Gene Cloning Services - Market Insights, Competitive Landscape, and Market Forecast - 2034"</a> has been added to ResearchAndMarkets.com's offering. The global DNA and gene cloning services market was valued at USD 4.20 billion in 2025 and is projected to reach USD 15.60 billion by 2034. The market is forecast to expand at a compound annual growth rate of 15.7% from 2026 to 2034, supported by rising demand for biologics, gene-based therapeutics, synthetic biology, and cell and gene therapy. Technological advances in gene synthesis, error correction, silicon-chip synthesis, automation, and artificial intelligence-enabled sequence design are improving throughput, accuracy, and project turnaround. Pharmaceutical companies, biotechnology organizations, academic institutions, and contract research and manufacturing organizations are also increasingly outsourcing molecular biology workflows to specialized DNA and gene cloning service providers. Key DNA and Gene Cloning Services Market Findings <ul><li>Gene synthesis led the market by service type, accounting for 38% of global revenue in 2025.</li><li>Drug discovery and development represented the largest application segment, with a 36% market share in 2025.</li><li>Pharmaceutical and biotechnology companies dominated the end-user category, capturing 44% of the market in 2025.</li><li>Research-use services accounted for 68% of the market by grade in 2025.</li><li>North America held the largest regional share at 41% in 2025.</li><li>Asia-Pacific is expected to record the fastest growth through 2034.</li></ul> Biologics and Gene-Based Therapeutics Accelerate Market Demand The expansion of monoclonal antibodies, recombinant proteins, messenger RNA vaccines, and gene therapies is a primary growth driver for the DNA and gene cloning services market. Therapeutic development programs require gene synthesis, expression vector construction, cloning, sequence optimization, and plasmid DNA production across discovery, preclinical, and clinical stages. Growing biologics pipelines and continued investment in cell and gene therapy are increasing demand for specialized service providers with scalable infrastructure, validated quality systems, and clinical-grade production capabilities. Good manufacturing practice cloning and plasmid production are expected to become increasingly important as more advanced therapies progress toward clinical development and commercialization. Synthetic Biology and Technology Innovation Support Expansion Synthetic biology applications-including metabolic engineering, protein engineering, antibody development, gene circuit construction, and variant library generation-are creating substantial demand for high-throughput gene synthesis and cloning. At the same time, advances in automation, sequence design, error correction, and artificial intelligence are helping providers manage increasingly complex constructs while reducing costs and delivery times. Gene synthesis remained the leading service category in 2025 because of its central role across therapeutic research, synthetic biology, genome editing, vaccine development, and recombinant protein production. Molecular cloning and subcloning, vector construction and mutagenesis, and plasmid preparation remain essential complementary services within integrated project workflows. Drug Discovery and Development Remains the Leading Application Drug discovery and development accounted for 36% of the DNA and gene cloning services market in 2025. Growth in this segment is supported by expanding pharmaceutical and biotechnology pipelines, particularly for antibodies, recombinant proteins, vaccines, and cell and gene therapies. Service providers support these programs through custom gene synthesis, codon optimization, vector construction, mutagenesis, cloning, and plasmid preparation. Demand is also increasing for end-to-end services that can support projects from early-stage research through clinical-grade production. Regional Market Outlook North America dominated the global DNA and gene cloning services market with a 41% share in 2025. The region benefits from an established biotechnology and pharmaceutical sector, substantial biomedical research funding, advanced laboratory infrastructure, and a high concentration of gene synthesis and cloning companies. The United States remains the largest national market, supported by continued investment in biologics, genomics, synthetic biology, and advanced therapies. Europe represents a significant market, led by Germany, the United Kingdom, France, Italy, and Spain. Regional demand is supported by pharmaceutical research, biotechnology development, academic funding, and the presence of established molecular biology service providers. Asia-Pacific is forecast to register the fastest growth through 2034. China, India, Japan, and South Korea are expanding biotechnology research, pharmaceutical development, contract manufacturing, and gene synthesis capacity. Rising investment, improved research infrastructure, and the regional expansion of global and domestic providers are expected to create substantial long-term opportunities. Latin America, the Middle East, and Africa offer emerging opportunities as healthcare investment, biomedical research, and biotechnology capabilities develop. Growth rates will vary according to local research capacity, funding availability, infrastructure, and access to specialized services. Competitive Landscape The DNA and gene cloning services market remains fragmented, with global life sciences companies, specialist gene synthesis providers, molecular biology service organizations, and regional participants competing on accuracy, throughput, quality, price, turnaround, vector availability, regulatory compliance, and production scale. Leading companies operating in the market include: <ul><li>GenScript Biotech Corporation</li><li>Thermo Fisher Scientific Inc.</li><li>Twist Bioscience Corporation</li><li>Integrated DNA Technologies, Inc.</li><li>Azenta, Inc., through GENEWIZ</li><li>ATUM</li><li>Eurofins Scientific SE</li><li>Takara Bio Inc.</li><li>Merck KGaA</li><li>Macrogen, Inc.</li></ul> Competitive investment is increasingly focused on higher-throughput synthesis, improved construct accuracy, automated sequence design, clinical-grade services, good manufacturing practice capacity, and biosecurity screening. Strategic partnerships, technology licensing, capacity expansion, and acquisitions are expected to continue shaping the market. Market Challenges Market growth may be moderated by the cost and technical complexity of long or difficult sequences, clinical-grade production requirements, intellectual property restrictions, export controls, and shortages of skilled molecular biology professionals. Differences in provider quality, turnaround, and verification standards can also affect downstream research and therapeutic development. Biosecurity screening has become an increasingly important operational requirement. Providers must maintain robust customer and sequence screening procedures while complying with applicable nucleic acid synthesis frameworks, export controls, and good manufacturing practice standards. These requirements may increase costs but also strengthen quality, security, and customer confidence. Recent DNA and Gene Cloning Services Market Developments In April 2024, the White House Office of Science and Technology Policy issued a framework for nucleic acid synthesis screening. The framework established expectations for screening synthetic nucleic acid sequences and customers, reinforcing biosecurity responsibilities across the gene synthesis industry. In May 2024, Twist Bioscience Corporation launched multiplexed gene fragments designed to support pooled DNA fragment synthesis and high-throughput screening. The development strengthened the company's position in synthetic biology and large-scale screening applications. Market Segmentation <ul><li>By service type: Gene synthesis; molecular cloning and subcloning; vector construction and mutagenesis; plasmid preparation and other services.</li><li>By application: Drug discovery and development; synthetic biology; academic and basic research; other applications.</li><li>By end-user: Pharmaceutical and biotechnology companies; academic and research institutes; contract research and manufacturing organizations; other end-users.</li><li>By grade: Research-use services; good manufacturing practice and clinical-grade services.</li><li>By geography: North America; Europe; Asia-Pacific; Latin America; the Middle East; and Africa.</li></ul> Market Outlook The DNA and gene cloning services market is positioned for strong growth through 2034 as therapeutic pipelines expand and organizations adopt outsourced, technology-enabled molecular biology services. Providers that combine broad service portfolios, rapid turnaround, verified accuracy, scalable manufacturing, regulatory compliance, and advanced biosecurity processes are expected to secure a competitive advantage. With gene synthesis leading service demand, drug discovery and development remaining the largest application, and pharmaceutical and biotechnology companies representing the principal customer group, the market offers significant opportunities for established providers and specialized entrants. North America is expected to retain its leading position, while Asia-Pacific is likely to generate the fastest expansion as regional biotechnology and pharmaceutical capabilities continue to advance. For more information about this report visit <a href="https://www.researchandmarkets.com/reports/6274242/dna-gene-cloning-services-market-insights?utm_source=GNE&amp;utm_medium=PressRelease&amp;utm_code=4rg43x&amp;utm_campaign=2346356+-+Global+DNA+and+Gene+Cloning+Services+Market+to+Reach+%2415.6+Billion+by+2034+as+Therapeutic+Pipelines+Expand+and+Organizations+Adopt+Outsourced%2c+Technology-Enabled+Molecular+Biology+Services&amp;utm_exec=jocamsai" rel="nofollow" target="_blank" title="">https://www.researchandmarkets.com/r/smdwaj</a> About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. <pre>CONTACT: 
CONTACT: ResearchAndMarkets.com 
 Laura Wood,Senior Press Manager 
 press@researchandmarkets.com
 For E.S.T Office Hours Call 1-917-300-0470 
 For U.S./ CAN Toll Free Call 1-800-526-8630 
 For GMT Office Hours Call +353-1-416-8900 

</pre> <img alt="" src='https://ml.globenewswire.com/media/NjVlMWZiZGEtZWQ4Mi00MDMyLTlhYTktZGM2OWRmYWQwNWZlLTEwMjY3MzctMjAyNi0wOS0wOS1lbg==/tiny/Research-and-Markets.png' referrerpolicy='no-referrer-when-downgrade' />

Global DNA and Gene Cloning Services Market to Reach $15.6 Billion by 2034 as Therapeutic Pipelines Expand and Organizations Adopt Outsourced, Technology-Enabled Molecular Biology Services

Latest news from the world of business and finance – both local and global

MONEY FM 89.3 is Singapore's first and only Business and Personal Finance station, featuring local and international business and financial news.

MONEY FM 89.3

Discover newsletters from our DJs on LinkedIn